ELC-201
Solid Tumors
PreclinicalActive
Key Facts
About Elicera Therapeutics
Elicera Therapeutics is a clinical-stage biotech focused on developing potent cell and gene therapies for aggressive and recurrent cancers, with a core mission to conquer solid tumors. Its foundational achievement is the patented iTANK platform, which enhances CAR T-cells to recruit the patient's own immune system, creating a multi-targeted attack. The company's strategy leverages a dual business model: advancing four internal therapeutic programs (two CAR T-cell and two oncolytic virus candidates) and generating near-term value through non-exclusive out-licensing of the iTANK technology. Recent recognition of its scientific founder as 'Cancer Researcher of the Year 2026' underscores the quality of its research foundation.
View full company profileTherapeutic Areas
Other Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| APVO603 | Aptevo Therapeutics | Preclinical |
| APVO711 | Aptevo Therapeutics | Preclinical |
| Platform-derived Immunotherapy | GenCirq | Pre-clinical |
| SP-2-225 | Shuttle Pharmaceuticals | Preclinical |
| SP-1-161 | Shuttle Pharmaceuticals | Preclinical |
| HBM1020 | Harbour BioMed | Phase 1 |
| HBM7022 | Harbour BioMed | Phase 1 |
| HBM9033 | Harbour BioMed | Discovery |
| Undisclosed Whole Cell Vaccine Program(s) | Neuvogen | Pre-clinical |
| SY-5609 | Syros Pharmaceuticals | Phase 1/2 |
| Not Specified (TCR Therapy) | T-Cure Bioscience | Phase 1 |
| B7-H3 Program | Ocean Biomedical | Discovery |